n 2022, the U.S. Food and Drug Administration (FDA) granted its first approval for the use of organoid and organ-on-a-chip technologies in new drug development research, marking a milestone in the field of biomedical research.
On September 21, we held a grand ceremony to mark the first shipment of NEST pen injectors produced at our Wuxi, China facility to our U.S. headquarters.
Following the FDA 510(k) clearance of NEST Repeatable Pen Injector, NEST Disposable Pen Injector Landed U.S. Food and Drug Administration (FDA) 510(k) Letter!
Dear customer:
Thank you for your continuous support and love for our products. In order to better meet your growing order needs and enhance your ordering experience, we decided to optimize and adjust the single carton quantity of Cryogenic Tubes. The specific changes are described as follows:
In June 2024, the pen injector independently developed and produced by Wuxi NEST Biotechnology Co., Ltd. (hereinafter referred to as NEST) won the US Food and Drug Administration (FDA) 510 (k) Letter!
List
• Article Title：Engineered poly(A)-surrogates for translational regulation and therapeutic biocomputation in mammalian cells. • Author：Jiawei Shao
• Journal Title：Cell Research
• Impact Factor：44.1
